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Abstract 
Ascertaining the dominant cell type driving an immunological disease is essential to 
understanding the causal pathology and, therefore, selecting or developing an effective 
treatment. Classifying immunological diseases in this way has led to successful treatment 
regimens for many monogenic diseases; however, when the dominant cell type is unclear 
and there is no obvious causal genetic mutation, then identifying the correct disease 
classification and appropriate therapy can be challenging. In this review we focus on 
pulmonary immunological diseases where an innate immune signature has been identified 
as a predominant aspect of the immunopathology. We describe the molecular pathology of 
 ‘ĂƵƚŽŝŶĨůĂŵŵĂƚŽƌǇĚŝƐĞĂƐĞƐŽĨƚŚĞůƵŶŐ ?ĂŶĚƉƌŽƉŽƐĞƚŚĂƚ small molecule and biologic 
therapies, including recombinant IL-1Ra, that target key innate immune pathways, are likely 
be beneficial in the control of pulmonary and systemic inflammation in these conditions. In 
addition, the successful use of macrolide antibiotics to treat lung infections in these 
conditions further adds to the growing body of evidence that the innate immune system is 
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the key conductor of inflammation in these pulmonary diseases, as there is a strong body of 
evidence that macrolides are able to modulate the NLRP3 inflammasome and IL-1E and IL-
18 secretion, both of which are central players in the innate immune response. Throughout 
this review we highlight the published evidence of autoinflammatory disease in COPD, 
bronchiectasis, cystic fibrosis (CF) and rheumatoid lung disease and suggest that the 
fundamental pathology of these diseases places them towards the autoinflammatory pole 
of the immunological disease continuum (IDC). 
 
Introduction 
The identification of an autoinflammatory basis for a significant proportion of human 
disease, has significantly modified the nosology of inflammatory disorders over the past two 
decades [1, 2]. The disease category, autoinflammation, was originally proposed to describe 
the underlying pathophysiology in a family of monogenic autosomal dominant periodic 
fever syndromes, but this classification has subsequently been applied to a broader range of 
disease entities, including polygenic ĂƵƚŽŝŶĨůĂŵŵĂƚŽƌǇĚŝƐĞĂƐĞ ?ƐƵĐŚĂƐƌŽŚŶ ?Ɛdisease, as 
well as specific major histocompatibility complex (MHC) class 1-associated conditions, such 
as ankylosing spondylitis, psoriatic arthropathy and Behcet ?Ɛ disease [3-5]. The term 
autoinflammation is based on central involvement of innate immune system activation, in 
association with a paucity of autoantibodies and autoantigen-specific T and B cells. 
Immunological diseases exist on a continuous spectrum, with autoimmune diseases, 
driven by the adaptive immune system, at one extreme, and autoinflammatory diseases, 
driven by the innate immune system, at the diametrically opposite end of that spectrum [3]. 
The majority of immunological diseases are located somewhere in the interval between the 
autoimmune and autoinflammatory ends of the continuum, often with some degree of 
amalgamation of these two systems driving the underlying pathology [2]. Diseases that are 
defined as wholly autoimmune or autoinflammatory in nature are most often the rare 
hereditary disorders associated with mutated genes/proteins in the underlying 
immunological innate or adaptive pathways. In that regard, the hereditary 
autoinflammatory diseases (HAIDs) constitute a set of conditions at the autoinflammatory 
end of the spectrum, which have arisen due to mutations within genes involved in the 
innate immune system, and leading to hyperresponsive or overactive innate immune 
responses [6]. HAIDs usually present with periodic episodes or flares, which are often 
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interleukin (IL)-1 mediated and are particularly responsive to anakinra, a recombinant IL-1 
receptor antagonist (IL-1ra) molecule, or, indeed, to other forms of IL-1 blockade, such as 
rilonacept and canakinumab. Rilonacept (IL-1 Trap) is a decoy receptor for IL-1, inhibiting 
both IL-1ɲ and IL-1ɴ signalling, while canakinumab is a humanised monoclonal antibody 
selectively binding to IL-1ɴ. HAIDs can be both monogenic and polygenic (Figure 1); there is 
considerable overlap between polygenic autoinflammatory diseases and MHC class 1 W
associated diseases [3]. The periodic episodes associated with HAIDs involve systemic multi-
organ inflammation, fevers, arthritic joint pains, skin rashes, abdominal pain and pulmonary 
inflammation. Characteristic flares, associated with HAIDs, are often triggered by exposure 
to specific environmental conditions or agents; for example, low temperatures may 
precipitate an attack of familial cold urticaria, which is one of the conditions that falls under 
the umbrella term, cryopyrin-associated periodic syndrome (CAPS). 
This review will propose that many immunological diseases which exhibit pulmonary 
manifestations, are driven by innate immune cells and can be situated towards the 
autoinflammatory pole of the IDC (Figure 1). We will also explore the molecular mechanisms 
of pulmonary flares in HAIDs and discuss the similarities in autoinflammatory pathology that 
are shared by many pulmonary immunological diseases at the molecular level. 
 
The pulmonary innate immune system 
 The pulmonary system is an integral part of the innate immune system, by providing 
crucial barrier function between the environment and the circulation, and by employing 
various mechanisms to prevent foreign bodies entering the body [7, 8]. The innate immune 
ƐǇƐƚĞŵ ?ƐŵĂŝŶƉƵƌƉŽƐĞŝƐto provide the initial outposts, in the form of toll like receptor 
(TLR), expressed on sentinel cells, such as macrophages and dendritic cells, to detect and 
respond to invading pathogens; this is achieved by the recognition of a broad range of 
structurally conserved molecules derived from microbes, termed pattern associated 
molecular patterns (PAMPs). In addition, damage-associated molecular patterns (DAMPs) 
are endogenous molecules, ƌĞůĞĂƐĞĚďǇƚŚĞŚŽƐƚ ?ƐĚĞĂĚŽƌĚǇŝŶŐĐĞůůƐ, which are also 
ƌĞĐŽŐŶŝƐĞĚďǇd>ZƐǁŝƚŚƚƌŝŐŐĞƌŝŶŐŽĨŝŶŶĂƚĞŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐŝŶƚŚĞůƵŶŐ ?Ɛ
microenvironment [8]. 
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The innate immune system of the lung is diverse in nature and includes itinerant 
leukocytes such as monocytes, neutrophils and macrophages, as well as structural cells, 
such as epithelial cells and fibroblasts. Dendritic cells and mast cells are of haematopoietic 
origin, but may be found in the lung and combine to orchestrate immune responses in that 
organ. A wide variety of microbiocidal soluble factors are secreted by cells of the innate 
immune system to counter invading pathogens. However, the pulmonary innate immune 
ƐǇƐƚĞŵĚŽĞƐŶ ?ƚũƵƐƚƌĞůǇŽŶmyeloid and haematopoietic immune cells for defence, as 
pulmonary epithelial cells are also a vital cell type in detection and prevention of spread by 
invasive foreign pathogens [8]. These epithelial cells are often targeted by both bacteria and 
viruses, which conspire to evade the immune system; however, the pulmonary epithelium is 
able to orchestrate the degree and magnitude of the inflammatory response as they express 
high levels of TLRs capable of detecting a broad range of PAMPs. Epithelial cells also 
undergo shedding [9-11], a process whereby they can mediate cell death and are 
subsequently replaced by a new layer of epithelial cells. This process reduces the spread of 
foreign organisms throughout the epithelial layers and, in the process, exposes intracellular 
pathogens to specialised phagocytic cells, such as macrophages and dendritic cells [12].  
The initiation of an innate immune response is mediated by a key set of cytokines. 
The IL-1 cytokine family is primarily comprised of innate proinflammatory cytokines and 
chemokines plus their antagonists and receptors. The most comprehensively studied IL-1 
cytokines are IL-1ɴĂŶĚ/>-18, both of which are inflammasome mediated [13]. The 
inflammasomes are key intracellular innate immune macromolecular protein complexes 
that require two signals to become primed and activated. Once activated, the 
inflammasomes bring inactive pro-caspase-1 and inactive zymogens, pro-IL-1ɴĂŶĚƉƌŽ-IL-
18, into close proximity. The pro-caspases then self-cleave in an autocatalytic reaction that 
culminates in the cleavage and activation of pro-IL-1ɴĂŶĚƉƌŽ-IL-18 into their active forms. 
IL-1ɴĂŶĚ/>-18 serve different proinflammatory purposes in fine tuning the innate immune 
response [14]. Haematopoietic innate immune cells predominantly secrete IL- ?ɴ ?ĂŚŝŐŚůǇ
biologically active proinflammatory cytokine that provokes a systemic inflammatory state by 
inducing fever and activation, with subsequent recruitment of other immune cells. Epithelial 
cells are reported to preferentially secrete IL-18 over IL- ?ɴ ?/>-18 is responsible for recruiting 
neutrophils to sites of inflammation as well as differentiating T-cells towards a Th17 and 
TH1 phenotypes and activating natural killer (NK) cells [15]. 
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The air we breathe contains damaging foreign bodies in abundance, all capable of 
initiating an innate immune response. The successful resolution of such proinflammatory 
responses is equally important to their initiation. Uncontrollable or excessive pulmonary 
inflammation is highly damaging, and conditions such as sepsis or chronic obstructive 
pulmonary disease (COPD) may arise from local inflammation that is not efficiently resolved 
(Figure 1). The inherent capacity of a host to initiate and resolve lung inflammation has 
further implications than merely containing specific lung conditions. Many chronic 
infections, in addition to cancers [16], heart disease [17] and immunological diseases, are 
thought to begin in the lung, either due to inadequate control of local infection or potent 
carcinogens, resulting in DNA mutation or the development of auto-antigens capable of 
breaking tolerance. As the lung is on the frontline in protecting against environmental 
injury, innate immune responses, including those of epithelial origin, are of particular 
importance in this regard [7]; if resolution or activation of these pivotal responses goes 
awry, then immunological disease may ensue. This review will explore the molecular 
mechanisms involved in chronic innate immune-mediated inflammation in the lung and will 
also examine the particular aspects of such autoinflammation which enable immunological 
disease progression. 
 
Autoinflammatory diseases 
        Respiratory manifestations may occur in many cases of autoinflammatory disease 
(Figure 1). This is in part due to the systemic nature of autoinflammation [18]. However, the 
innate immune response within HAIDs is one that is primed and hyperresponsive and when 
innate immune cells come into contact with antigens entering the lung, the response will 
often turn out to be inappropriate and prolonged. Recurrent and severe respiratory 
infections often coincide with the periodic flares associated with autoinflammatory disease 
[19]. Recurrent respiratory tract infections, often pneumonia, as well as restrictive lung 
disease and interstitial fibrosis occurs in spondyloenchondrodysplasia with immune 
dysregulation (SPENCDI) [20], STING-associated vasculopathy with onset in infancy (SAVI) 
[21], and acute febrile neutrophilic dermatosis (^ǁĞĞƚ ?s syndrome).  
Other autoinflammatory diseases may also develop acute respiratory distress syndrome 
(ARDS), a condition in which high levels of autoinflammation increase the alveolocapillary 
space, thereby impairing oxygen gas exchange with consequent reduced blood oxygenation. 
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ARDS has been observed in adult-ŽŶƐĞƚ^ƚŝůů ?ƐĚŝƐĞĂƐĞ [22, 23], familial haemophagocytic 
lymphohistiocytosis (FHL) [24], and NLRC4-related macrophage activation-like syndrome 
(MAS) [25-28], resulting in pulmonary fibrosis. Autoinflammation and PLCG2-associated 
antibody deficiency and immune dysregulation (APLAID) has been described as manifesting 
with respiratory bronchiolitis and recurrent sinopulmonary infections, driven by innate 
immune cellular infiltrations (neutrophils, eosinophils, histiocytes, and lymphocytes (Figure 
1) [29], with reduced IgA and IgM levels and memory B-cells [29]. 
        The fact that autoinflammatory diseases present with pulmonary inflammation 
confirms that the lung is a site vulnerable to chronic, unresolved innate immune-mediated 
damage (Figure 1). Therefore, immunological diseases, where the lung is the primary site of 
chronic inflammation, could be expected to develop a predominantly innate immune 
signature [30]. Where pulmonary innate immune cells respond inappropriately, excessively 
and without proper resolution, this can be thought of as autoinflammatory disease of the 
lung. As described above, autoinflammatory diseases, although self-perpetuating require a 
specific trigger(s) in order to develop into a characteristic systemic flare; indeed, this is also 
the case for many pulmonary immunological diseases.  
 
Macrolides 
Rapamycin is a macrolide antibiotic with potent immunosuppressor activity. The drug is 
widely used in vitro as an inhibitor of NLRP3 inflammasome. The introduction of other 
macrolides including erythromycin, clarithromycin and azithromycin appear to have similar 
anti-inflammatory and immunomodulatory properties [31, 32].They reduce IL- ?ɴĂŶĚ/>-6 
responses to challenge with LPS and decrease bacterial burden, lung inflammation and, in 
the mouse model, enhance bacterial clearance of Burkholderia cepacia (B. cepacia) complex 
through induction of autophagy [31-34]. The macrolide, azithromycin, has also been shown 
to have anti-inflammatory effects in bronchiectasis, as it enhances the clearance of 
apoptotic cells, such as neutrophils, by improved macrophage phagocytic function [35, 36]. 
Non-antibiotic macrolide derivatives have also been shown to inhibit LPS induced mucus 
production, neutrophil infiltration and the production of inflammatory cytokines and 
suppression of IL-1E induced NF-NB activation in airway epithelial cells[37]. 
Low-dose macrolide therapy can reduce pulmonary exacerbation rates in patients suffering 
from various lung diseases including CF, non-CF bronchiectasis, COPD, asthma, bronchiolitis 
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obliterans syndrome, diffuse panbronchiolitis (DPB), chronic rhinosinusitis (CRS) [38-42]. 
This class of drug has both anti-inflammatory and immunomodulatory effects, which are 
independent of antimicrobial activity. Low doses of macrolide inhibit the innate immune 
response, as well as altering the lung microbiota and bacterial quorum sensing [43, 44]. 
Individual response to low dose macrolides therapy, in conditions such as COPD and 
bronchiectasis, is variable and may reflect differences in aetiology as well as the balance 
between infection and autoinflammation. 
 
Diffuse Panbronchiolitis 
Several prospective clinical trials of macrolides in CF have shown variable  improvements in 
lung function, weight, quality of life and a reduction in pulmonary exacerbations [45]. These 
studies were prompted by the successful use of erythromycin in DPB, a disease of chronic 
airway inflammation and sinobronchial infection [37, 46]. The aetiology of DPB remains 
unclear although there are both environmental and genetic predisposing factors, with most 
cases occurring in East Asia [37, 47-51]. This condition shares some features with CF and, if 
left untreated, may result in disease progression, bronchiectasis and end-stage lung disease. 
Like CF, DPB is associated with endobronchial neutrophilic inflammation, with elevation of 
IL-1 beta (IL-1E) and IL-8 levels in the lungs [52-54]. In the respiratory bronchioles, 
lymphocytic inflammation appears to predominate, with peribronchial infiltration by 
lymphocytes, plasma cells and histiocytes [55]. Inhibition of this inflammatory response by 
low-dose macrolides supports a significant autoinflammatory component to the disease.  
 
Chronic Obstructive Pulmonary Disease 
       Chronic obstructive pulmonary disease (COPD) is leading cause of death worldwide and 
the condition is characterised by chronic bronchitis, airway obstruction and emphysema. 
Smoking is the primary cause of COPD and triggers an autoinflammatory response through 
induction of ROS, acquired dysfunction of the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein, impaired autophagy, ER stress and activation of the unfolded 
protein response (UPR) [56-58]. This inflammatory process is unable to resolve effectively 
and is ultimately highly destructive, manifesting in chronic bronchitis and emphysema [59-
61]. There is evidence for an autoinflammatory signature in individuals with COPD, 
suggesting there may be a genetic predisposition beyond alpha-1-antitrypsin deficiency, 
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which, when combined with chronic exposure to external stimuli, may progresses to COPD 
[62]. The various clinical subtypes of COPD may reflect variation in the balance between 
inflammation and infection, as well as disease aetiology.  
The external stimuli that trigger COPD are numerous and comprehensive, and embody both 
infectious organisms and noxious chemicals, such as those found in cigarette smoke (Figure 
1). dŚŝƐĨĞĂƚƵƌĞŽĨKW ?ƐƉĂƚŚŽŐĞŶĞƐŝƐŝƐƐŚĂƌĞĚǁŝƚŚŵĂŶǇ,/Ɛ ?/ŶĂĚĚŝƚŝŽŶƚŽ
similarities in disease onset, the type of inflammation in COPD also bears many parallels 
with HAIDs. A strong IL-1E, IL-6, IL-18, IL-27 and IL-33 signature has been found in the lungs 
of individuals with COPD, as well as macrophage and neutrophilic infiltrations [63-65]. A 
recent study by Faner et al. [64], described how the NLRP3 inflammasome is primed in 
COPD patients and that during exacerbations (ECOPD) the pre-primed NLRP3 inflammasome 
releases an excess of IL-1E family cytokines into the surrounding tissues. Further evidence 
for IL-1E-driven inflammation in COPD has been demonstrated in a COPD mouse model, 
whereby tobacco smoke inhalation over 10 months was used to induce COPD in NLRP3
-/-
 
and wild-type mice [66]. NLRP3
-/-
 developed no pulmonary lung damage or IL-1E secretion 
related to the smoke inhalation. In addition, the levels of innate immune cellular infiltration 
were significantly higher in COPD mice compared to NLRP3
-/-
. This suggests that NLRP3-
mediated IL-1E drives COPD pathology and that chronic NLRP3 priming prevents resolution 
of COPD lung inflammation. Another study found no significant increase in NLRP3 or IL-1E 
cytokines in COPD patientƐ ? lung samples; however, the IL-7 level was elevated in COPD 
[65]. In the lung IL-7 is secreted by epithelial cells, which then drives monocytic and T-cell-
mediated inflammation. This suggests that IL-7 may be recruiting inflammatory cells into the 
COPD lung and thereby supporting and prolonging the inflammation. Trials of low-dose 
macrolides have demonstrated clinical benefit with a reduction in pulmonary exacerbations, 
increased time to next exacerbation and improved quality of life. Patients who are not 
actively smoking appear to gain greater benefit, possibly reflecting persistence of 
autoinflammation in the absence of a primary trigger [67] [68].These data support the 
notion that COPD is towards the autoinflammatory end of the IDC and that established 
COPD has an intrinsic priming of the innate IL-1E cytokine pathway. A positive response to 
low-dose macrolide therapy may reflect a subgroup of individuals where autoinflammation 
is driving disease progression. Despite evidence for overexpression of NLRP3 in the lung of 
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stable COPD patients, treatment with anti-IL- ?ɴ ?ĂŶƚŝ-IL-1R1 and anti-IL-18 monoclonal 
antibodies have not proved beneficial. 
 
Non-cystic fibrosis bronchiectasis 
Bronchiectasis is a complex heterogeneous group of disorders with different underlying 
aetiologies, presenting with varied prevalence across geography and ethnicity, indicating 
both environmental and genetic links to disease susceptibility [69].  The term 
bronchiectasis, refers to the permanent dilatation of the airways due to airway injury and 
remodeling, as a consequence of infection, inflammation and auto-immune disease [69, 70]. 
Chronic inflammation remains a key component of bronchiectasis with autoinflammation 
often driving disease progression even in the absence of active infection. Inflammation 
occurs in in the bronchial wall, mainly of the smaller airways, with predominantly 
macrophages and lymphocytes (mainly T cells) migrating into the cell wall [71-73], with the 
neutrophils being the most prominent cell type occupying the bronchial lumen [71, 73]. 
Once neutrophils have migrated to sites of infection in the lungs, they move along a 
chemoattractant gradient (e.g. IL-8, LTB4, TNF and IL-1E) and switch to their antimicrobial 
function [74]. By contrast, elevation in IL-13 reflects a more eosinophilic phenotype and an 
exaggerated IL-17 response occurs in primary immunodeficiency [75-77]. The increased 
number of apoptotic neutrophils in the airways, indicates the failure of phagocytic cells such 
as macrophages to clear the apoptotic cells, leading to increased inflammation and airway 
damage, through the uncontrolled release of the neutrophils granular contents [78, 79]. 
Bronchial epithelial cells excessively secrete pro-inflammatory cytokines and express 
adhesion molecules such as ICAM-1 when stimulated with a bacterial trigger [80-82]. This 
results in the recruitment of neutrophils to the site of infection, exacerbating inflammation.  
Neutrophilic airway inflammation can persist in the absence of infection, and the vicious 
circle of host-mediated autoinflammation can be further exacerbated by the presence of 
chronic bronchial sepsis [83]. 
 
Cystic fibrosis 
      Cystic Fibrosis (CF) is one of the most common life threatening genetically inherited 
conditions affecting Caucasians. The disease is caused by an absence or defect in the CFTR 
protein which is expressed throughout the body. In the lung defective CFTR function results 
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in abnormal ion transport, dehydrated airway surface liquid and abnormal mucociliary 
clearance. These changes lead to recurrent infections, hypoxia, anaerobic biofilm formation, 
innate immune cell infiltration, excessive inflammation and bronchiectasis. Epithelial cells 
do not exclusively express the CFTR, with strong evidence that fibroblasts, lymphomas, 
leukemia cells, lymphocytes, neutrophils, monocytes, and alveolar macrophages also 
express the CFTR protein. Reduced CFTR expression and Cl
-
 flux have also been shown in CF 
monocytes. Therefore, with both epithelial cells and innate immune cells being affected by 
the CFTR mutation and with a clinical presentation of disproportionate pulmonary 
inflammation, CF is firmly located towards the autoinflammatory end of the IDC. 
Evidence for autoinflammatory disease in the CF lung exists in a recent study showing 
that showed that IL-1ɴƐĞĐƌĞƚŝŽŶĂŶĚE>ZW ? inflammasome activation are exaggerated in 
Pseudomonas aeruginosa (P. aeruginosa) infection in murine CF [84]. Data suggesting NLRP3 
inflammasome-dependent secretion of IL- ?ɴŝƐĞůĞǀĂƚĞĚŝŶcftr-/- mice also indicate that 
elevated IL-1E secretion in CF is intensified by insufficient NLRC4-mediated IL-1ra 
production. This study proposes that further genetic deficiency within NLRC4 or IL1RN (IL-
1ra gene) would exacerbate and predispose to severe autoinflammatory lung disease in CF. 
Among the highlights of this elegant study include reduced bacterial colonisation of cftr-/- 
mice after anakinra treatment, which was corroborated by reduced inflammation in both 
cftr-/- mice and human epithelial cells treated with anakinra. The authors advocate the use 
of anakinra therapy in CF, as their data show an anakinra-dependent reduction in NLRP3 
inflammasome activation, by not merely assuaging IL- ?ɴproduction but also by inducing 
autophagy and thus NLRP3-inflammasome degradation. 
In addition to an excessive response to bacterial infection, the intrinsic defect in CF 
predisposes innate immune cells towards a proinflammatory phenotype, with a decrease in 
alternatively activated, anti-inflammatory M2 phenotype macrophages [85]. This is a 
hallmark of autoinflammatory diseases such as MAS [25, 26, 28] and deficiency of adenosine 
deaminase 2 (DADA2), an inherited cause of vasculitis [86, 87].  
Data suggesting that mitochondrial calcium (Ca
2+
) and the mitochondrial Ca
2+
 uniporter 
(MCU) have a role in supporting NLRP3 inflammasome signalling in CF support the idea that 
inflammation in CF is autoinflammatory-based [88]. Dysfunctional or mutated CFTR perturbs 
intracellular Ca
2+
 signalling, in combination with P. aeruginosa infection, and decreases 
mitochondrial membrane potential, increases mitochondrial fragmentation and induces 
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mitochondrial ROS (mROS) production. This study clearly outlines the role exerted by PA 
infection, and specifically flagellin/TLR5/Myd88 signalling, on the integrity and function of 
the mitochondria and how this mitochondrial damage induces exaggerated inflammatory 
responses in CF. The authors focused on NLRP3-mediated inflammation, as CF lung disease 
is often characterised by IL- ?ɴĂĐĐƵŵƵůĂƚŝŽŶ ?By using sophisticated silencing experiments, 
they described mitochondrial perturbation as being upstream of NLRP3 inflammasome 
activation and that P. aeruginosa flagellin amplified this activation via a Ca
2+
 -dependent 
mechanism. The mitochondrial dysfunction caused by loss of CFTR function is driven by PA 
infection and associated NLRP3 activation, leading to susceptibility to the pathogen. The 
mitochondrial dysfunction was dependent on MCU expression as the channel facilitated the 
influx of calcium into the mitochondria. The fact that mitochondrial dysfunction and mROS 
production activated NLRP3 supplements the evidence for an autoinflammatory disease 
process in the CF lung.  
A key aspect of immunological diseases is that the underlying inflammation is sterile, 
despite infection being one of the triggers. The above studies both used infection models to 
elucidate the extent to which CF is an IL-1-mediated disease. However, the fact that there is 
an IL-1 signature does not automatically assign CF to a place among the autoinflammatory 
diseases. A feature of CF is periodic pulmonary infection and, therefore, it is important to 
establish whether the intrinsic CFTR defect is the root cause of the inflammation, rather 
than the recurrent infections. Animal model studies have demonstrated that CF does 
produce sterile inflammation in the lung when animals are housed in germ-free 
environments. These animals develop lung and gut inflammation despite the absence of 
microorganisms. This is due to the fact that colonisation of the lung and gut after birth leads 
to life-long periodic lung infections, thus providing a constant trigger for CFTR
mut
-dependent 
autoinflammation. 
There is also strong evidence for the presence of elevated oxidative stress in CF [89-91]. 
Oxidative stress with associated ROS production is a known activator of innate immune 
signalling and aberrant NLRP3-inflammasome activation. 
Due to the nature of the disease, misfolded CFTR protein is often present in many 
genetic classes of CF. Misfolded proteins drive many autoinflammatory diseases, such as 
tumour necrosis factor (TNF)-receptor associated periodic fever syndrome (TRAPS) and 
familial Mediterranean fever (FMF) and generate intrinsic endoplasmic reticulum (ER) stress 
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that serves to prime and initiate proinflammatory signalling pathways via the UPR. XBP1, a 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐƉůŝĐĞĚĂŶĚĂĐƚŝǀĂƚĞĚďǇ/Z ?ɲ, is a major arm of the UPR, and induces 
proinflammatory cytokine signalling; CF and TRAPS have this pathophysiology in common. 
To summarise, CF fits the characteristics of a HAID, due to the combined effects of several 
aberrant molecular pathways being adversely affected by loss of CFTR function and the 
presence of defective protein integrity, which results in the autoinflammatory phenotype of 
CF.  
 
Rheumatoid arthritis lung disease 
        Rheumatoid arthritis (RA) is a systemic inflammatory disorder, affecting about 0.7-1.0% 
of adults of Western European ancestry, which is characterized by synovial inflammation 
and swelling that may ultimately lead to erosive destructive changes in cartilage and bone 
[92]. The disease is usually associated with the presence of autoantibodies, including 
rheumatoid factor (Rh Factor) and antibodies to citrullinated protein antigens (ACPA), in 
over 60% of patients [93]. Patients with RA frequently have extra-articular manifestations, 
including vasculitis, inflammatory eye disease and lung disease. There is considerable 
debate about when and where the inflammation begins in RA; in this regard, a number of 
initiating sites of inflammation have been proposed for the immune-mediated injury in RA 
[94]. These include oral bacteria [95] as well as gut microbiota [96], and a number of studies 
have suggested that the systemic inflammation originates within the lungs, with cigarette 
smoking being a potent inducer of RA [97, 98], for poorly understood mechanisms.  
       Although RA is often considered as an autoimmune disease, the pathophysiology has 
many innate immune signatures and it may be better placed along the IDC, rather than at 
the autoimmune end of the spectrum. The recent definition of immunologically-defined 
disease subsets of RA, using immunohistochemistry (IHC) and gene expression data, from 
both synovial tissues [99, 100] and blood (TACERA), has led to an improved understanding 
of the complex pathobiology of RA. Different synovial phenotypes in RA have been 
correlated with response to biologic therapeutics, with the myeloid (innate immune-
mediated) and lymphoid (predominantly adaptive immune-mediated) phenotypes being 
associated with differential clinical responses; the myeloid subtype responds primarily to 
anti-TNF, and the adaptive subtype responds better to anti-IL6R therapy, especially in later 
RA [99]. These studies have created a paradigm shift in the classification of RA, with the 
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autoimmune subtype being associated with the presence of autoantibodies and the myeloid 
subtype more likely to be driven by innate immune mechanisms. 
         A wide range of lung diseases may be associated with RA, including bronchiectasis, 
pulmonary parenchymal disease (interstitial lung disease (ILD)(Figure 1), bronchiectasis, 
bronchiolitis (predominantly obliterative in nature), and inflammation of the pleura (pleural 
thickening and effusions), and diseases of the pulmonary vasculature (vasculitis and 
pulmonary hypertension). These changes may reflect increased susceptibility to infection 
(often related to medications), chronic immune activation, or toxicity from disease 
modifying or biological therapies. 
        A recent study by Lasithiotaki et al. investigated the role of the NLRP3 inflammasome in 
rheumatoid lung disease, both idiopathic pulmonary fibrosis (IPF) and RA Wusual interstitial 
pneumonia (RA-UIP) by using in vitro stimulation studies of patient bronchoalveolar lavage 
fluid (BALF) samples [101]. There were distinct NLRP3 inflammasome activation profiles 
between patients with IPF and RA-UIP. Both IL-1E and IL-18 levels were elevated in RA-UIP 
BALF, and also in BALF macrophages before and after stimulation in RA-UIP, suggesting pre-
existing NLRP3 inflammasome activation in these patients. These observations were further 
supported by the elevated IL-18 levels, in particular, being decreased by caspase-1 inhibition 
in RA-UIP but not in IPF, as caspase-1 maturation and release is mediated by NLRP3 
inflammasome activation [102]. Therefore, this study provides evidence for RA-UIP being 
essentially an innate immune-driven autoinflammatory condition, despite the authors ? 
conclusion that the disease is autoimmune. Furthermore, there was failure of NLRP3 
inflammasome activation in alveolar macrophages in BALF samples from the patients with 
IPF, and it was proposed that this impaired activation may be a key mechanism in 
generating the autoinflammatory fibrotic phenotype in IPF.   
       There is an emerging body of work regarding the role of the microbiome in lung disease 
and the potential for gut or oral microbiota to contribute to the pathogenesis of these 
conditions and also, indeed, to beneficially modulate innate immune response [103]. 
Furthermore, there is evidence for neural regulation of innate immunity, as a coordinated 
host response to pathogens [104]. However, these studies are still in their infancy and the 
tools to decipher the complexity of relationship between the microbiome, the central 
nervous system and immune regulation of disease are not yet available. We can expect 
these to be areas of intensive research effort in the near future.  
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Conclusions 
       Autoinflammation is an emerging component of a growing number of diseases and 
understanding their immunopathogenesis is an important endeavour that will lead to 
greater personalisation of therapies, with targeting of pathways and cytokines that are 
relevant to disease pathogenesis. This process involves reassessing already-characterised 
diseases in order to elucidate disease subsets that may be identifiable after more detailed 
probing of the immune signatures involved. Many lung diseases have not yet been 
recognised as part of the immunological disease spectrum, and characterising them in this 
way may reveal new pathogenic pathways that are targetable by existing small molecules 
and/or biologics. 
         The pathologies of many chronic respiratory diseases involve a combination of genetic 
and environmental factors that, working in concert, prime and activate innate immune-
associated inflammation. This scenario is typical of autoinflammatory diseases, particularly 
the HAIDs. This review has highlighted aspects of COPD, bronchiectasis, CF and RA lung 
disease that are quintessentially autoinflammatory in nature and has proposed that the 
core pathologies of these diseases place them towards the autoinflammatory pole of the 
IDC. 
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